Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come

Seattle Genetics, Inc.: Double-Digit Revenue Growth, but the Best Is Yet to Come

Sales of Seattle Genetics's (NASDAQ: SGEN) Adcetris in the U.S. and Canada jumped 13% year over year in the third quarter, but it's still a relatively small seller for a cancer drug, especially considering that Adcetris has been on the market for six years. Fortunately, sales should accelerate from here with an expanded approval under review at the FDA and another one ready to be submitted soon.

Metric

Q3 2017

Continue reading

Source: Fool.com